| Joshua Lee Dillon, MD | |
|
1350 Hickory St, Melbourne, FL 32901-3224 | |
| (407) 975-0410 | |
| (407) 975-0413 |
| Full Name | Joshua Lee Dillon |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 1350 Hickory St, Melbourne, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124227582 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 45942 (Tennessee) | Secondary |
| 208M00000X | Hospitalist | ME139888 (Florida) | Secondary |
| 208000000X | Pediatrics | ME139888 (Florida) | Primary |
| Entity Name | Florida Hospital Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225034234 PECOS PAC ID: 0749186153 Enrollment ID: O20031208000807 |
News Archive
VaxInnate Corporation today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services, worth up to $196 million to fund the development of recombinant seasonal and pandemic flu vaccines.
Semafore Pharmaceuticals today announced today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,662,977 entitled "PI-3 Kinase Inhibitor Prodrugs." This composition of matter patent covers a genus of novel compounds that includes SF1126, Semafore's clinical stage, small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival.
Endo announced today that it has reached an agreement with Watson Pharmaceuticals (Watson) resolving two patent infringement lawsuits related to LIDODERM.
Æterna Zentaris Inc., a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the initiation, by its partner Keryx Biopharmaceuticals Inc., of a Phase 3 registration clinical trial for perifosine (KRX-0401), the Company's PI3K/Akt pathway inhibitor, in relapsed/refractory multiple myeloma patients.
Today, the Indiana State Legislature's Criminal Law and Sentencing Policy Study Committee is holding a hearing on how the state can improve its policies for preventing the illegal diversion of pseudoephedrine (PSE) a key ingredient in leading cold and allergy medicines for methamphetamine production.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joshua Lee Dillon, MD 1350 Hickory St, Melbourne, FL 32901-3224 Ph: (407) 975-0410 | Joshua Lee Dillon, MD 1350 Hickory St, Melbourne, FL 32901-3224 Ph: (407) 975-0410 |
News Archive
VaxInnate Corporation today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services, worth up to $196 million to fund the development of recombinant seasonal and pandemic flu vaccines.
Semafore Pharmaceuticals today announced today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,662,977 entitled "PI-3 Kinase Inhibitor Prodrugs." This composition of matter patent covers a genus of novel compounds that includes SF1126, Semafore's clinical stage, small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival.
Endo announced today that it has reached an agreement with Watson Pharmaceuticals (Watson) resolving two patent infringement lawsuits related to LIDODERM.
Æterna Zentaris Inc., a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the initiation, by its partner Keryx Biopharmaceuticals Inc., of a Phase 3 registration clinical trial for perifosine (KRX-0401), the Company's PI3K/Akt pathway inhibitor, in relapsed/refractory multiple myeloma patients.
Today, the Indiana State Legislature's Criminal Law and Sentencing Policy Study Committee is holding a hearing on how the state can improve its policies for preventing the illegal diversion of pseudoephedrine (PSE) a key ingredient in leading cold and allergy medicines for methamphetamine production.
› Verified 1 days ago
Dr. Hiep Le Nguyen, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1755 W Hibiscus Blvd, Melbourne, FL 32901 Phone: 321-724-5437 Fax: 321-724-5570 | |
Dr. Robert E Leiba, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1755 W Hibiscus Blvd, Melbourne, FL 32901 Phone: 321-724-5437 Fax: 321-724-5570 | |
Dr. Omar Dean Hudson, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1223 Gateway Dr Ste 1g, Melbourne, FL 32901 Phone: 321-723-0072 Fax: 321-952-0850 | |
Brenda Lis Figueras, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 2120 Sarno Rd, Melbourne, FL 32935 Phone: 321-241-6800 Fax: 321-241-6888 | |
Dr. Julio Daniel Vallette Jr., M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1350 S Hickory St, Melbourne, FL 32901 Phone: 321-434-7243 | |
Dr. Faris M. Al-mousily, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 3021 W Eau Gallie Blvd Ste 101, Melbourne, FL 32934 Phone: 321-275-5444 Fax: 321-275-3799 | |
Dr. Jamie Lee Clute, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1350 Hickory St, Melbourne, FL 32901 Phone: 321-434-7208 Fax: 321-434-5344 |